SITC 2021 | Tmod™: a new way to distinguish cancer cells from normal cells

Alexander Kamb, PhD, A2 Biotherapeutics, Agoura Hills, CA, give us an overview of the Tmod™ (T-cell module) mechanism and platform. In contrast to other molecules that distinguish between tumor and normal cells by targeting specific mutations or overexpressed proteins on the tumor cell surface, Tmod™ uses tumor-specific gene deletion as a source of discrimination between normal and cancer cells. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.